Top-Line Results of Solanezumab Phase 3 Clinical Trial Announced by Lilly

Lilly

Nov. 23, 2016

Eli Lilly and Company has announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial. This is a phase 3 study of solanezumab in people with mild dementia due to Alzheimer’s disease (AD). Patients treated with solanezumab did not experience a statistically significant slowing in cognitive decline compared to patients treated with placebo (p=.095), as measured by the ADAS-Cog14 (Alzheimer’s Disease Assessment Scale-Cognitive subscale). No new safety signals were identified in the study. Lilly has decided not to pursue regulatory submissions for solanezumab for the treatment of mild dementia due to Alzheimer’s disease.

John C. Lechleiter, Ph.D., chairman, president and chief executive officer, Lilly, said: “The results of the solanezumab EXPEDITION3 trial were not what we had hoped for and we are disappointed for the millions of people waiting for a potential disease-modifying treatment for Alzheimer’s disease. We will evaluate the impact of these results on the development plans for solanezumab and our other Alzheimer’s pipeline assets.”

“Lilly is grateful for the dedication of the patients, their families, and the clinical investigators who participated in this study. Lilly remains committed to Alzheimer’s research as we have been for nearly 30 years, and our portfolio includes many other promising approaches,” said Jan Lundberg, Ph.D., executive vice president of science and technology and president of Lilly Research Laboratories.

Advertisements

One thought on “Top-Line Results of Solanezumab Phase 3 Clinical Trial Announced by Lilly

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s